Withings ECG-Monitor Study

Atrial Fibrillation Clinical Trial

Official title:

Validation of WBS08 With Withings ECG Monitor for the Detection of Atrial Fibrillation

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05316337
• Other study ID #: WBS08-ECG
• Status: Completed
• Phase: N/A
• Start date: July 15, 2022
• Est. completion date: September 1, 2023

Study information

• Verified date: March 2024
• Source: Withings
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of the study is to evaluate the performance of Withings WBS08 with embedded Withings ECG Monitor in the automatic detection of atrial fibrillation

Recruitment information / eligibility

• Status: Completed
• Enrollment: 650
• Est. completion date: September 1, 2023
• Est. primary completion date: September 1, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 22 Years and older

Eligibility

Inclusion Criteria:

• Male or female who are 22 years of age or older,

• Subject able to read, understand, and provide written informed consent,

• Subject willing and able to participate in the study procedures as described in the consent form,

• Subject able to communicate effectively with and willing to follow instructions from the study staff.

Exclusion Criteria:

• Vulnerable subject with regard to regulations in force

• Subject who is deprived of liberty by judicial, medical or administrative decision,

• Underage subject,

• Legally protected subject, or subject who is unable, linguistic or psychic incapacity, to sign the written informed consent form.

• Subject within several of the above categories,

• Subject who refused to participate in the study,

• Subject mentally impaired resulting in limited ability to cooperate

• Subject with electrical stimulation by pacemaker

• Patient with pathologic disorder that may affect motricity resulting in significant tremor that prevents subject from being able to hold still (e.g Parkinson disease)

• Patient unable to stay in an upright position for the duration of study measures

• Acute myocardial infarction (MI) within 90 days of screening or other cardiovascular disease that, in the opinion of the Investigator, may increase the risk to the subject or renders data uninterpretable (e.g., recent or ongoing unstable angina, decompensated heart failure, active myocarditis or pericarditis)

• Acute pulmonary embolism or pulmonary infarction, within 90 days of screening

• Stroke or transient ischemic attack within 90 days of screening

• Active life-threatening rhythms as determined by the investigator (ventricular tachycardia, ventricular fibrillation, 3 rd -degree heart block).

• History of life-threatening rhythms as determined by the investigator (ventricular tachycardia, ventricular fibrillation, 3 rd -degree heart block)

• Symptomatic (or active) allergic skin reactions such as eczema, rosacea, impetigo, dermatomyositis or allergic contact dermatitis over electrode attachment sites

• Known sensitivity to medical adhesives, isopropyl alcohol, or electrocardiogram (ECG) electrodes including known allergy or sensitivity to fluoroelastomer bands

• Weight more than 180 kg

Related Conditions & MeSH terms

• Atrial Fibrillation

Intervention

Device:
• Electrocardiogram recording
ECG recording with investigational device
• Electrocardiogram recording
ECG recording with reference device

Locations

Country	Name	City	State
France	Henri-Mondor Hospital	Créteil	Île De France
United States	Cambridge Medical Trials	Alexandria	Louisiana
United States	FWD Clinical Research	Boca Raton	Florida
United States	Florida Cardiovascular Research	Hialeah	Florida
United States	Texas Heart Institute	Houston	Texas
United States	American Institute of Therapeutics	Lake Bluff	Illinois
United States	Diverse Clinical Research	Miami	Florida
United States	The Angel Medical Research	Miami Lakes	Florida
United States	Heartbeat Health	New York	New York
United States	LINQ Research LLC	Pearland	Texas

Sponsors (2)

Lead Sponsor	Collaborator
Withings	Syntactx

Countries where clinical trial is conducted

United States,  France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Co-primary outcomes	Sensitivity (percentage of true positives) in detecting AF from conclusive recordings generated by the software under test, that is recordings resulting in a classification of AF or SR by the SUT, compared to the reference 12-lead ECG.	4 months
Primary	Co-primary outcomes	Specificity (percentage of true negatives) in detecting AF from conclusive recordings generated by the software under test, that is recordings resulting in a classification of AF or SR by the SUT, compared to the reference 12-lead ECG.	4 months
Secondary	Evaluation of the classification into heart rate subgroups	The classification into heart rate subgroups will be evaluated for the pairs of strips such that the rhythm classification of the 12-lead ECG is either SR or AF and such that the strip generated by the SUT is classified as either SR or AF. The evaluation will be assessed with the concordance of classifications, i.e. the percentage P of identical classifications by the SUT and the reference method, into each of the four following subgroups: SR with a HR between 50 and 99 bpm; SR with a HR between 100 and 150 bpm; AF with a HR between 50 and 99 bpm; AF with a HR between 100 and 150 bpm	4 months
Secondary	Clinical Equivalence of ECG waveforms	Clinical Equivalence of ECG waveforms will be qualitatively and quantitatively assessed between the 6-leads generated by the SUT and the leads I, II, III, aVR, aVL, aVF of the 12-lead ECG by a board of certified cardiologists: The visibility and polarity of the P waves, QRS complexes and T waves will be determined by cardiologists and according to a set of predetermined rules. For each type of wave (P, QRS and T),	4 months
Secondary	Clinical Equivalence of ECG waveforms	The durations of the QT intervals, QRS complex widths, and PR intervals will be measured by cardiologists with a caliper and according to a set of predetermined rules for each of the 6 leads of the strips generated by the SUT and the leads I, II, III, aVR, aVL, aVF of the 12-lead ECG.	4 months
Secondary	Heart Rate equivalence	heart rate will be determined by independent cardiologists, or cardiac technicians supervised by cardiologists, from each six-channel strip recorded with the SUT and from each lead I, II, III, aVR, aVL, aVF of the 12-lead reference ECG	4 months